Trademarkia Logo

Canada

C$
Gofyxiiq
SEARCHED

on 25 Jul 2024

Last Applicant/ Owned by

CSL Behring GmbH

Emil-von-Behring Str. 7635041Marburg

DE

Serial Number

2290499 filed on 20th Sept 2023

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 2600, 160 ELGIN STREETOTTAWA

ONTARIO

CA

K1P1C3

Gofyxiiq

Trademark usage description

pharmaceutical preparations, namely, blood plasma, blood plasma fractions, protein arrays for medical diagnosis purposes, stem cells for veterinary pu Read More

Classification Information


Class [005]
Pharmaceutical preparations, namely, blood plasma, blood plasma fractions, protein arrays for medical diagnosis purposes, stem cells for veterinary purposes, stem cells for medical purposes, blood culture media for medical and veterinary purposes, and blood for medical purposes; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of hereditary angioedema (HAE); pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS); pharmaceutical preparations for the treatment of idiopathic pulmonary fibrosis (IPF); pharmaceutical preparations for the treatment of interstitial lung disease (ILD); pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, influenza and respiratory diseases and disorders; antibodies for medical use, namely, pharmaceutical antibodies for the treatment of hereditary angioedema (HAE), respiratory diseases and respiratory syndromes, for auto-immune diseases, and for the prevention and treatment of auto-immune diseases; antibodies for medical use, namely, pharmaceutical antibodies for the treatment of acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), and interstitial lung disease (ILD); antibodies for medical use, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing, namely COVID-19, coronavirus disease, influenza and respiratory diseases and disorders.


Classification kind code

12

Mark Details


Serial Number

2290499

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 22
on 25th Jul 2024
Search Recorded
Submitted for opposition 20
on 25th Jul 2024
Examiner's First Report
Submitted for opposition 223
on 25th Jul 2024
Total Provisional Refusal
Submitted for opposition 257
on 25th Jan 2024
Designation Notification - Madrid Protocol
Submitted for opposition 210
on 25th Jan 2024
IR Correction
Submitted for opposition 257
on 2th Nov 2023
Designation Notification - Madrid Protocol
Submitted for opposition 31
on 1st Nov 2023
Formalized
Submitted for opposition 1
on 1st Nov 2023
Created
Submitted for opposition 228
on 20th Sept 2023
International Registration
Submitted for opposition 30
on 20th Sept 2023
Filed